Literature DB >> 21932140

In vitro activity of beta-lactam antibiotics to community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

C Germel1, A Haag, B Söderquist.   

Abstract

Community-associated (CA) MRSA often display low MIC values against oxacillin. The in vitro activity of various beta-lactam antibiotics against heterogeneous CA-MRSA (n = 98) isolated in a low endemic area was determined by Etest, and Mueller-Hinton agar (MUHAP) was compared with Mueller-Hinton agar supplemented with 2% NaCl (MUHSP). In general, the CA-MRSA isolates showed higher MIC values for the various beta-lactam antibiotics on MUHSP compared with MUHAP. MIC values for oxacillin ranged from 1 to >256 mg/L on MUHSP. Cephalothin, representing the first generation of cephalosporins, showed MICs from 0.75 to 96 mg/L and the MIC(50) and MIC(90) for cefuroxime, cefotaxime and cefepime, representing the second, third and fourth generations, respectively, were rather high. However, the MIC(50) and MIC(90) for ceftobiprole (fifth generation) were 1.5 and 2 mg/L, respectively, on MUHSP. The MIC(50) and MIC(90) for imipenem were 0.75 and 2 mg/L, respectively, on MUHSP. Only 3/98 (3%) CA-MRSA isolates showed a MIC >4 mg/L. Consequently, low MIC values for imipenem, lower than those of the newly developed fifth generation cephalosporins, were found among CA-MRSA. These findings may be considered for further studies including clinical trials in order to evaluate carbapenems as a potential treatment option for infections caused by CA-MRSA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21932140     DOI: 10.1007/s10096-011-1333-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains.

Authors:  Xiao Xue Ma; Teruyo Ito; Chuntima Tiensasitorn; Mantana Jamklang; Piriyaporn Chongtrakool; Susan Boyle-Vavra; Robert S Daum; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

2.  Predominance of staphylococcal cassette chromosome mec (SCCmec) type IV among methicillin-resistant Staphylococcus aureus (MRSA) in a Swedish county and presence of unknown SCCmec types with Panton-Valentine leukocidin genes.

Authors:  C Berglund; P Mölling; L Sjöberg; B Söderquist
Journal:  Clin Microbiol Infect       Date:  2005-06       Impact factor: 8.067

3.  Superior in vitro activity of carbapenems over anti-methicillin-resistant Staphylococcus aureus (MRSA) and some related antimicrobial agents for community-acquired MRSA but not for hospital-acquired MRSA.

Authors:  Tomomi Takano; Wataru Higuchi; Tatsuo Yamamoto
Journal:  J Infect Chemother       Date:  2009-03-12       Impact factor: 2.211

4.  Classification of staphylococcal cassette chromosome mec (SCCmec): guidelines for reporting novel SCCmec elements.

Authors: 
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

5.  Use of broth enrichment and real-time PCR to exclude the presence of methicillin-resistant Staphylococcus aureus in clinical samples: a sensitive screening approach.

Authors:  P Nilsson; H Alexandersson; T Ripa
Journal:  Clin Microbiol Infect       Date:  2005-12       Impact factor: 8.067

6.  Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus.

Authors:  T Ito; Y Katayama; K Asada; N Mori; K Tsutsumimoto; C Tiensasitorn; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

7.  Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors:  Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

8.  Phenotypic detection of methicillin resistance in Staphylococcus aureus by disk diffusion testing and Etest on Mueller-Hinton agar.

Authors:  R Skov; R Smyth; A R Larsen; A Bolmstrôm; A Karlsson; K Mills; N Frimodt-Moller; G Kahlmeter
Journal:  J Clin Microbiol       Date:  2006-10-18       Impact factor: 5.948

9.  Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.

Authors:  Steven N Leonard; Chrissy M Cheung; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

Review 10.  Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era.

Authors:  Frank R DeLeo; Henry F Chambers
Journal:  J Clin Invest       Date:  2009-09       Impact factor: 14.808

View more
  4 in total

1.  Rationale for eliminating Staphylococcus breakpoints for β-lactam agents other than penicillin, oxacillin or cefoxitin, and ceftaroline.

Authors:  Jennifer Dien Bard; Janet A Hindler; Howard S Gold; Brandi Limbago
Journal:  Clin Infect Dis       Date:  2014-01-22       Impact factor: 9.079

2.  Managing Severe Community-Acquired Pneumonia Due to Community Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Jason C Kwong; Kyra Chua; Patrick G P Charles
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

3.  A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.

Authors:  Samir S Awad; Alejandro H Rodriguez; Yin-Ching Chuang; Zsuszanna Marjanek; Alex J Pareigis; Gilmar Reis; Thomas W L Scheeren; Alejandro S Sánchez; Xin Zhou; Mikaël Saulay; Marc Engelhardt
Journal:  Clin Infect Dis       Date:  2014-04-09       Impact factor: 9.079

Review 4.  Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.

Authors:  Christopher A Darlow; Renata M A da Costa; Sally Ellis; François Franceschi; Mike Sharland; Laura Piddock; Shampa Das; William Hope
Journal:  Paediatr Drugs       Date:  2021-08-26       Impact factor: 3.022

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.